News
January 21, 2021
Data published in Molecular Diagnostics & Therapy demonstrate how Secarna’s powerful bioinformatics generate improved LNA-modified antisense oligonucleotide therapies
January 21, 2021
January 19, 2021
Antisense oligonucleotide candidate derived from Secarna Pharmaceuticals’ LNAplusTM platform has entered pre-clinical safety trials for the treatment of elevated blood lipids
October 13, 2020
Secarna Pharmaceuticals and Denali Therapeutics enter into research and option agreement to develop novel antisense therapies in the field of neurodegenerative diseases
October 13, 2020
August 5, 2020
Secarna Pharmaceuticals and Evotec form strategic partnership in the field of antisense therapy
April 28, 2020
Secarna Pharmaceuticals enters into cooperation with Guangzhou’s Sun Yat-sen University to develop a treatment for SARS-CoV-2 viral infections
April 28, 2020
March 27, 2018
BIO-Europe Spring® 2018 / Secarna MD Jonas Renz on standing out in a crowd